Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
The RCVS Disciplinary Committee has reprimanded and warned a Clwyd-based veterinary surgeon on charges relating to falsifying prescriptions to obtain drugs for her own use.
At the outset of the two-day hearing, Mrs Alina Grecko admitted that in 2009 she had written out three prescriptions for her own use whilst working as a veterinary surgeon at Greenfield Veterinary Surgery, Holywell, Clywd, and that this amounted to serious professional misconduct. The Committee found this to be the case, and said she was right to admit it. The Committee also said this was deliberate wrong-doing on three separate occasions and involved an obvious breach of Mrs Grecko's legal duties in relation to prescription which was bound to diminish the profession and public confidence in it. It was also a flagrant breach of the Guide to Professional Conduct for Veterinary Surgeons.
In the Committee's opinion the charge was a serious one; it involved falsehoods and disregard of legal obligations and of the profession's standards, as well as compromising another professional - a pharmacist. In mitigation, however, the Committee accepted that the offence involved no harm to any animal or person, nor risk of harm except to herself; nor was there financial gain. Mrs Grecko was a young and relatively inexperienced veterinary surgeon, and the Committee's view was that the offence was the result of her not thinking straight at a time of great stress in her personal and professional life, rather than a clearly thought out course of deliberate conduct. It was in no doubt that Mrs Grecko was genuinely remorseful about her behaviour and had insight into its seriousness.
The Committee also considered evidence relating to the circumstances in which the prescription came to be written. It accepted the general case that the original idea of self-prescribing did not come from Mrs Grecko; however, the Committee did not find that she had been encouraged or persuaded; the most that could be said was that Mrs Grecko had taken up a casual suggestion that she might write the prescription herself.
When deciding on sanction, the Committee took into account both the facts of the particular case and the mitigating factors. It reiterated that the primary purpose of the sanction is not to punish the Respondent but to protect the welfare of animals, to maintain public confidence in the profession, and to uphold proper standards of conduct and said the sanction applied must be proportionate to the nature and extent of the Respondent's conduct, and weigh the public interest with the interests of the Respondent. The Committee also said that in a case involving the writing of false prescriptions the importance of public confidence in the profession and of upholding the standards of the profession mean that the Committee would normally feel that at least a suspension from the Register should be imposed.
Having given anxious consideration to the question whether that course could properly be avoided in this case, the Committee felt able to take an exceptional course and the sanctions it has imposed are that the Respondent will both be reprimanded and warned as to her future conduct. It directed that these sanctions will remain on her record indefinitely.
The authors say that whilst it has long been suspected that adverse drug reactions are under-reported, this study is the first to show the scale of the problem, using real data from veterinary clinical records.
For the study, researchers looked for electronic heath records within the Small Animal Veterinary Surveillance Network (SAVSNET) which contained “adverse drug reactions” and “side effects” in the free-text clinical narratives.
The results were then analysed to determine the suspected product, the seriousness and expectedness of the event, and whether the event had been reported to the Veterinary Medicines Directorate or Marketing Authorisation Holders.
Of the 827 cases of suspected adverse drug reactions identified out of a total of 10,565 records reviewed, approximately 90% were not reported.
74% were related to dogs and 70% were listed as “expected” (i.e. already listed in the product information).
The clinical severity of the reaction didn’t appear to impact whether it was reported.
Dr Heather Davies, lead author of the study, said: “As adverse drug reaction reporting rate is directly linked to the regulators ability to mitigate safety issues, this paper is a call to arms encouraging all veterinary professionals to report suspected adverse drug reactions and regulators to make reporting quicker and easier.
"It also the highlights the promise that big real-world data sets hold in enhancing drug safety monitoring processes.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13721
Dechra Veterinary Products has launched a new online fluid therapy distance-learning course for vets and nurses, to help maximise the potential of its Vetivex® fluids range.
The Fluids Knowledge Programme has been created to provide comprehensive and flexible online CPD for companion animal and equine practitioners. The coursework, which counts for six to eight hours of CPD learning, includes the latest thinking from fluid therapy specialists Dr Ava Firth, Karen Humm and Kevin Corley.
Dechra says the course combines theoretical and practical advice on fluid therapy for both small animals and horses, and can be used for training, as a refresher, and to develop thinking on fluid therapy. Self-assessment questions included within the course allow progress to be monitored throughout.
Gwenda Bason, marketing director for Dechra Veterinary Products, said: "We've spent months of research and development producing this online learning portal for professionals. It will enable vets and nurses to improve their knowledge, understanding and patient care. Being online, users can dip in and out of it as and when their schedules allow and additional costs often associated with CPD learning, such as travel or accommodation costs, are eliminated.
"When practices choose Vetivex, they're not just buying bags of fluid, they're benefitting from our investment in practice education which will improve their understanding of the role and management of fluids."
Dechra estimates the programme is worth around £400 per person, and therefore offers savings of over £3000 in CPD costs for an 8 member practice.
To find out more about the Fluids Knowledge Programme visit www.fluidtherapy.co.uk, or contact Liz Rawlings at Dechra on 01743 441 632.
The company says it has already used part of the funding facility to acquire six practices – four in Wales and two in South London, with the aim to attain many more practices in 2017 across the UK.
Medivet now has 169 veterinary practices across the country, making it the fourth largest veterinary group in the UK.
Will Taylor, Corporate Relationship Manager for HSBC in Thames Valley, said: "It is great to see that Medivet has gone from strength-to-strength over the past few years, with an ambitious business. HSBC has enjoyed a long-standing and highly effective business relationship with Medivet and this latest deal will allow the business to carry out its aspiring acquisition plan and continue to grow at a rapid pace."
Dr Arnold Levy, Chief Executive Officer at Medivet, said: "This latest round of funding will allow us to take up a vast amount of opportunities that have become available to us and accelerate the pace of acquisitions of further practices across the country. Last year we acquired over 50 new sites and this year we plan to attain even more, which is significant progress for our business and testament to our strong financial backing."
The researchers say that ultimately the study should help with the development of guidelines to help all riders assess if they are the right weight for the horse or pony they intend to ride, to enhance both equine welfare and rider comfort and enjoyment.1
Dr Sue Dyson, Head of Clinical Orthopaedics at the Animal Health Trust’s Centre for Equine Studies, Newmarket, who led the study said: "While all the horses finished the study moving as well as when they started, the results showed a substantial temporary effect of rider weight as a proportion of horse weight.
"The results do not mean that heavy riders should not ride but suggest that if they do they should ride a horse of appropriate size and fitness, with a saddle that is correctly fitted for both horse and rider.
"We must remember that this is a pilot study: further work is required to determine if horse fitness, adaptation to heavier weights and more ideal saddle fit will increase the weight an individual horse can carry. This should help us further in our quest to develop guidelines for optimum rider: horse bodyweight ratios."
As the average weight and height of humans continues to increase there is growing debate about relative rider-horse sizes, with riding school horses epitomising the variety of weights of rider that a single horse may be exposed to.
Numerous inter-related aspects are involved with the horse and rider combination including the age of the horse, its fitness and muscle development, the length of its back and the presence or absence of lameness. The rider’s skill, fitness, balance and coordination are important factors, as is the fit of the saddle to both the horse and rider. The type, speed and duration of work and the terrain over which the horse is ridden must also be considered.2
To date little research has been conducted on the effects of rider weight on equine welfare and performance. To address the shortfall World Horse Welfare, the Saddle Research Trust, the British Equestrian Federation and a number of other organisations helped to fund a pilot study last summer, the results of which have now been analysed.
The influence of rider to horse bodyweight ratios on equine gait and behaviour: a pilot study1 assessed gait and behavioural responses in six horses ridden by four riders of similar ability but different sizes. The riders were all weighed in their riding kit and were subsequently categorised as being light, moderate, heavy and very heavy. Their body mass index (BMI) was also calculated.
Each rider rode each horse in its usual tack and performed a set pattern of exercises comprising mainly trot and canter. Gait, horse behaviour, forces under the saddle, the response to palpation of the back, alterations in back dimensions in response to exercise, heart and respiratory rates, salivary cortisol levels and blink rate were assessed for each combination.
The riding tests for the heavy and very heavy riders were all abandoned, predominantly because of temporary horse lameness. This was likely to have been induced by bodyweight rather than BMI, given that the heavy and moderate riders had similar BMIs, both being classified as overweight, yet only one of the moderate rider’s tests had to be abandoned. An ethogram, developed by Dr Dyson specifically to assess behavioural markers which may reflect pain in ridden horses3, was applied. The scores which may reflect pain were significantly higher in the horses when ridden by the heavy and very heavy riders.
The study also raised the issue of rider height and saddle fit. The owner of one of the test horses had a similar bodyweight: horse bodyweight ratio to the heavy rider and was of similar weight, but significantly different in height (157.0 and 185.5 cm, respectively). This large difference in height has major potential implications for saddle fit for the rider and consequently the rider’s position and weight distribution. The taller rider sat on the back of the cantle, overloading the back of the saddle and making it more difficult to ride in balance, with the heel being in front of a vertical line between the shoulder and ‘hip’.
Roly Owers, Chief Executive of World Horse Welfare, said: "These pilot results are certainly not surprising but are very significant in adding vital evidence to inform an appropriate rider: horse weight ratio. It is common sense that rider weight impacts equine welfare however many might not fully understand or recognise this. What is desperately needed is basic guidance to help riders identify a horse or pony that is right for them and this research is a vital step in that direction.”
The study was generously supported by World Horse Welfare, the Saddle Research Trust, Frank Dyson, British Equestrian Federation, British Horse Society, Pony Club, Polocross, The Showing Council, The Showing Register, The Society of Master Saddlers, Riding for the Disabled, British Eventing, British Dressage, the British Horse Foundation, the Worshipful Company of Saddlers and Endurance GB.
References
This year the congress is being organised in collaboration with the British Veterinary Dermatology Study Group and will form the Group’s autumn meeting.
The main scientific topics are skin and ear surgery, skin biology, host-microbial interaction, dermatophytosis, exotics dermatology and clinical pharmacology. There will be a three-tiered programme:
Basic level: providing updates on the topics covered
Intermediate level: advanced information for those with a good grounding in veterinary dermatology
Advanced level: more specialist subjects, including human dermatology
For the first time, there will also be a dedicated nurses programme, taking place on Saturday 28th September.
Laura Buckley CertVD DipECVD MRCVS, Local Organising Committee (pictured right), said: "Congress is always a major event in the veterinary dermatology calendar, featuring some of the world’s leading specialists, and this year showcases some of Liverpool’s spectacular historic sites.
"As always there will be commercial and poster exhibitions featuring state-of-the-art veterinary products and leading research in veterinary dermatology respectively."
This year’s social programme includes the Welcome Reception on Thursday 26th and the Dinner Dance on Friday 27th September. The Welcome Reception will be held at Liverpool’s Anglican Cathedral, designed by Sir Giles Gilbert Scott. It is the largest Cathedral in the UK and the fifth largest in the world.
The Dinner Dance will take place at Revolución de Cuba overlooking the UNESCO World Heritage Site, the Albert Dock.
For further information and to register please visit the congress website: www.esvd-ecvdcongress.com
Ceva Animal Health has announced that Vetergesic (buprenorphine), its long-lasting analgesic, is now back in stock and on special offer with the rest of the company's analgesic product range.
The company says it has appointed a new, dedicated Vetergesic manufacturing site and increased stock-holding facilities in order to guarantee a continuous long-term supply of the product, which is available in a 10ml vial for use in dogs, cats and horses and a 1ml single dose preparation for cats and dogs.
At the same time, Ceva has launched a spring offer on its entire analgesic product range, which runs till the end of April. For every two packs of Vetergesic, Carprodyl F or Dolagis purchased, veterinary practices will receive one pack free and for every four packs of Meloxidyl purchased, practices will receive one pack free. In addition, practices will be able to take advantage of ongoing rebates through the new CevaSave Rebate Programme.
For further information, contact your local Ceva territory manager, email analgesics-group@ceva.com or call 01494 781510.
Bayer Animal Health has launched Renalzin®, a feed additive for the management of Chronic Renal Disease (CRD), the leading cause of morbidity and mortality, especially in older cats1.
One-third of all cats over 15 years of age have CRD2, but the disease often remains undetected until the cat suddenly falls ill, by which stage 85% of kidney function may have already been lost3. The clinical signs are often subtle and non-specific, and diagnosis is complicated by the fact that changes in laboratory values occur relatively late in the disease.
Dr. Dennis Chew, specialist in veterinary urology and nephrology at the Ohio State University, said: "Most veterinary surgeons understand that CRD affects many cats, especially as they age, and is a leading cause of death. CRD is difficult to identify in early stages - early intervention with treatment can prevent progression of CRD to those with more serious kidney deficits. Restriction of dietary phosphorus intake is known to be a pivotal beneficial step in the stabilisation of CRD. Renalzin is a paste specifically formulated for cats that prevents dietary phosphate absorption across the intestine - a beneficial effect is gained when added to the cat's normal diet or to a veterinary renal diet".
The main ingredient of Renalzin is Bayer-registered Lantharenol® (lanthanum carbonate), a phosphate binder which binds to dietary phosphate within the gastrointestinal tract. According to the company, this renders it indigestible and thereby eases the burden on the already damaged kidneys.
Renalzin contains two additional ingredients - kaolin and vitamin E. Kaolin is a toxin binder which helps to reduce the absorption of toxins from the gastrointestinal tract. Vitamin E is known to reduce free radicals, improving immunity and protecting the integrity of cell membranes.
Bayer says that clinical studies demonstrate that Renalzin significantly increases faecal elimination and decreases urinary excretion of phosphorus 5. The product also decreases phosphate digestibility (absorption) in cats that are on both high and lower phosphate diets6. In addition, studies have shown that Renalzin causes a decrease in serum phosphate levels in cats with standard maintenance diets non-restricted in phosphorus7. Finally, a clinical trial in feline CRD patients revealed that taking Renalzin resulted in improvements in general clinical examination parameters as assessed by their veterinary surgeons over a two month period in cats on a normal diet7.
Renalzin comes in a pump applicator. One pump action provides 1 ml, with 2 ml being the recommended daily dose applied to and/or mixed with the cat's food. Having a neutral taste and being odourless, Renalzin® does not change the flavour of the cat's food and is flexible for clients to use as it can be given once or twice daily depending on the cat's feeding pattern.
References1 Lulich JP, O'Brien TD, Osbourne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Cd Cont Ed Pract Vet 1992, 14(2): 127 - 151.2 Polzin DJ, Osbourne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinarian Therapy X1. Philadelphia, PA, Saunders, 1992: 848-853.3 Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Animal 2005, 35: 581-596.4 http://en.wikipedia.org/wiki/Lanthanum_carbonate.5 Schmidt B et al Bay 78-1887, J Vet Pharmacol Therap 2006, 29 (Suppl 1): 206-2076 Schmidt B, Spiecker-Hauser U, Gropp J. Effecrt of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats. Proc Soc Nutr Physiol (2008) 17, in press.7 Data submitted for publication.
Norbrook Laboratories has launched Noroseal, a new teat sealant containing a unique anti-infective ingredient.
The company says that Noroseal, a 2.6g intramammary suspension, is the only teat sealant in the market-place in Europe to contain a PVP-Iodine excipient.
Dr Barry McInerney MVB, MRCVS, PhD, Norbrook GB Veterinary Advisor said: "Noroseal, with its unique formulation, offers vets a proven barrier against intramammary infections during the dry period.
"New bacterial infections occur most often during the first three weeks of drying off because the cow's natural keratin plug is not completely formed. Indeed, approximately 50% of teat canals are still open for up to seven days after drying off. Noroseal Teat Sealant will mimic the cow's keratin teat barrier offering immediate protection against infection. Additionally, the anti-infective ingredient, PVP-Iodine, complements the effectiveness of the teat-sealant components in the teat canal barrier."
Norbrook says that the estimated annual cost of mastitis to the UK dairy industry is in excess of £168M with a single case of clinical mastitis costing farmers approximately £178.00 per cow.
Dr McInerney added: "Clinical mastitis is a costly business but one that can be avoided if timely action is taken. There are various treatments available for dealing with mastitis but studies have shown that the risk of clinical mastitis may be reduced by up to 50% by using a combination of teat sealant and dry cow intramammary therapy. Noroseal is therefore an ideal combination with Norbrook's dry cow therapies such as Noroclox DC, Bovaclox DC Xtra and Bovaclox DC."
Noroseal is available in packs of 24 or buckets of 120 units. A range of promotional material is also available to veterinary practices via the Norbrook Sales Team.
Two winners will be flown from a London airport to spend 2 nights at the Krka Terme Hotel Svoboda Strunjan, a night at the Grand Union Hotel Ljubljana and a night at the Grand Hotel Bled, plus car hire.
To enter, visit www.discoverkrka.co.uk and pick out the differences between the Dalmations.
Ned Flaxman from Krka said: "I’ve only recently joined KRKA and I’m sure like many people I imagined Slovenia to be some far-off country in Eastern Europe. But it’s much closer than you might think - being only a couple hour’s boat ride from Venice.
"I would urge anyone to enter the competition to be in with the chance of winning this truly memorable trip. From the cliffs and stunning beaches of Strunjan to the lively and beautiful city of Ljubljana, Slovenia is a hidden gem just waiting to be discovered."
The company says that Daxocox achieves significant improvement of clinical signs associated with the pain of osteoarthritis (OA) in dogs1,2 and also helps reduce the risk of breakthrough pain.
Breakthrough pain is defined as “an abrupt, short-lived, and intense pain that breaks through the analgesia that controls pain”3. Risk factors for breakthrough pain in cases of canine OA include poor owner compliance, variable plasma drug levels between doses, natural or exercise induced flare-ups and disease progression.
According to research carried out by the company, veterinary surgeons estimate that nearly half of their canine OA cases on daily NSAIDs experience breakthrough pain4, whilst owners put the figure much higher at 80%5.
Animalcare says that as well as compromising patient welfare and increasing the risk of clinical consequences such as wind-up pain (hypersensitisation), breakthrough pain risks owners losing confidence in their vet and/or the recommended treatment plan for their dog. This may lead owners to independently stray from the treatment plan, with potentially damaging consequences. In its research, 87% of vets agreed that avoiding breakthrough pain is critical to the management of canine OA4.
Animalcare adds that because of the pharmacology, there is no risk of risk of over-accumulation or need for mandatory treatment ‘breaks’6. Also, adverse effects were found to be no different from any other NSAID1,2 and there was no increase in treatment-related adverse effects at up to 5 times the recommended dose7, so Daxocox has a broad margin of safety and is well tolerated by dogs7.
James Beaumont, marketing manager at Animalcare said: “Daxocox’s weekly administration of a flavoured tablet addresses some of the challenges of managing canine OA that I’m certain most vets will identify with. Breakthrough pain is a real problem and by being able to provide consistent pain control, in a compliance friendly formulation, Daxocox is a real game changer for canine OA management.
For more information, visit: www.animalcare.co.uk, or contact your local Animalcare territory manager, or Animalcare’s head office on 01904 487687.
References:
The ideal Christmas present for a vet to give a child has just landed on my desk.
It's the Amazing ABC Adventure by Lorna Maxwell, out now in paperback from Long Barn Books and available on Amazon here.
Each letter of the alphabet begins an eclectic list of things to be found within a delightful illustration on the facing page. There's a strong animal theme throughout the book: everything from annoyed armadillos and affectionate alligators to worried wombats and yodelling yaks.
One of those books that it's a pleasure to read a child before bed. A steal at £5.79.
John Davies and Tom Lonsdale MsRCVS both objected to edits made by the College to their candidate statements.
Mr Davies explained in his statement how he'd been subject to "bewildering, unfounded and damaging allegations" from two veterinary nurses, one of which he says resulted in his dismissal from a practice at which he was a partner. He went on to explain how, in addition to taking the dismissal case to an employment tribunal and winning, he had also raised concerns with the College about the nurses who'd made the allegations against him. Mr Davies outlined the way he felt that the RCVS mismanaged his case and how that had driven him to stand for Council to try and address the grave concerns he now had about the governance of the profession. However, the Returning Officer redacted the details on the grounds that they were considered to be defamatory and/or factually misleading.
The main grounds for Mr Lonsdale’s challenge was that the election had been furthered by corrupt practices, namely undue influence (all in terms of the Misrepresentation of the People Act 1983). In addition, the Returning Officer edited Mr Lonsdale’s candidate statement before circulation to the electorate, refusing to include hypertext links and removing references that the Returning Officer believed to be defamatory. The Returning Officer also declined to publish his ‘Quiz the candidates’ video on the RCVS website and/or YouTube channel when requests to make minor amendments considered defamatory were refused.
Both challenges were lodged with the RCVS last July, after which the College set up a Challenge Committee in accordance with the election challenge procedure, approved by Privy Council. It comprised three members of Council nominated by RCVS President Stephen May.
Sitting with one of the RCVS Legal Assessors – Mr Richard Price OBE QC – the Challenge Committee was required to decide whether to declare the election void, based on whether the alleged irregularity in question rendered the election substantially not in accordance with the RCVS Council Election Scheme, or that the irregularity concerned significantly affected the result of the election (in which Mr Lonsdale and Mr Davies came 15th and 16th respectively out of 16 candidates).
Following written submissions from both the RCVS and Mr Davies, the Challenge Committee dismissed Mr Davies’s challenge, stating that there was no irregularity in the conduct of the election on the part of the Returning Officer, and that there was no valid basis for challenging the validity of the election.
The Challenge Committee (comprising the same members as for Mr Davies’s challenge) also dismissed Mr Lonsdale’s challenge, stating that it considered it to be 'totally devoid of merit'.
Prior to reaching this decisions, however, two preliminary challenges made by Mr Lonsdale were also considered and dismissed.
The first related to the members of the Challenge Committee, whom Mr Lonsdale argued should stand down on the basis of actual or apparent bias based on his allegations of connections with the pet food industry.
The Committee considered that a fair-minded and informed observer, having understood the facts, would conclude that the connection of committee members to the pet food industry were '….remote, indirect and, in the case of one panel member, virtually non-existent'.
Each committee member was satisfied that there was '…no real possibility of their judgement being distorted or influenced by any interest in, or links with, the pet food industry.'
The second challenge was to The Legal Assessor, who had been appointed to advise the Committee. Mr Lonsdale had alleged that Mr Price had displayed bias in the way that he had given advice to the Committee in relation to the challenge to the Committee membership. This was also dismissed.
The new course is called Veterinary Science: Accelerated Graduate Entry (BVSc), and will welcome its first students in September 2019.
The school says the course responds to calls for innovation in veterinary education while upholding current best practice in adult education to support independent, self-directed, and collaborative learning.
Designed for graduate learners, the programme will see students guided through case-based, tutor-facilitated teaching and learning.
The programme is based on a collaborative approach, where students can work together to gain practical experience from BVS clinics and clinical research.
Students will be taught in new purpose-built teaching facilities at the school in Langford, North Somerset.
The Langford Campus also encompasses equine and small animal hospitals, a dairy farm, diagnostic laboratories, and farm animal, small animal and equine practices.
Professor Richard Hammond, Head of Bristol Veterinary School said: "As someone who was a graduate entry veterinary student myself, I feel passionately about providing opportunities to those who make the choice to train as a vet later in their educational journey.
"This new programme, delivered in purpose built, state-of-the-art facilities will focus on a more student-centred, case-based approach in small groups and with lots of tutor contact and support. We look forward to welcoming our first cohort of students to Bristol in September 2019".
The Prince's Trust 'creates life-changing opportunities' for those aged 11-30 and Nick has long-held a passion for making a difference to young lives. He has set up three charities for young people: with learning disabilities; who want to campaign to change the world; and who want to break down the barriers to enjoying nature and the outdoors.
Nick has led the RCVS since September 2012. During his tenure, developments at the College include a new Royal Charter, major governance reform, improved regulation of veterinary nurses, the instigation of Vet Futures, the introduction of the alternative dispute resolution service, significant evolution within the Practice Standards Scheme, the refocusing of RCVS Trust into RCVS Knowledge, the launch of Mind Matters, and the recognition of the College as a Great Place to Work.
Nick said: "It has been a great privilege to be CEO of the College and to work with such amazing staff, such a progressive Council and such a decent and caring profession. It is no surprise to me that vets and vet nurses are among the most trusted professionals in this country, and in my view this is due to their professionalism and to the excellence of the Royal College in maintaining and advancing standards. I hope I have played my part in helping the College and the profession navigate through a period of great change and preparation for significant change to come.
"At The Prince’s Trust I will be focused on the next generation, helping to give young people the confidence and purpose they need to make a success of their lives and the world around them. I know from my own personal experiences of school, and the various charities with which I have been involved, how many young people are not given the best chance in life. I cannot think of a better mission to take on."
RCVS President Chris Tufnell said: "I feel very fortunate to have worked closely with Nick over his five years with the RCVS; he has made a tremendous contribution to the College and our professions. With his energy and drive, he has infused the College with a culture of openness, engagement and dedication and has inspired the team through some impressive achievements.
"Nick’s leadership will enable vets and veterinary nurses to fulfil their potential and it's fitting that he's moving on to a role which benefits the lives of others. Meanwhile, there's a considerable amount of important work being done by the RCVS and I am confident that we have a strong team at Belgravia House to manage this until the new CEO is in post."
The RCVS says its Operational Board will be reflecting on Nick’s successes and the future needs of the College, before developing a specification for the new CEO and a recruitment process over the coming weeks.
7,383 veterinary surgeons voted in this year's election, a turnout of 19.7%.
This compares to turnouts of 16.7% in 2023, 18.6% in 2022, 24.5% in 2021, and 26.2% in 2020.
Of the 14 candidates, Professor David Barratt, Sinead Bennett and Zara Kennedy were all elected to serve for a four year term, with 1,747 votes, 1,796 and 2,264 votes respectively.
Mark Bowen (1,404), Richard Brown (1,030), Paddy Gordon (1,612), Gerard Henry (1,157), Peter Higgins (496), Penelope Morgan (1,584), Kate Richards (1,264), Richard Sanderson (1,380), Sally Schroeder (1,630), Lara Wilson (1,399) and the inevitable Thomas Lonsdale (257) were all unsuccessful.
The winning candidates will take up their posts at Royal College Day, which is open to all vets to attend on Friday 5th July at the Royal Institute of British Architects.
www.rcvs.org.uk/vetvote24
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
The company says the initiative, which is targeted at veterinary professionals and farmers, will be supported by an extensive social media, advertising and PR campaign.
The social media campaign will take the form of social media content, newsletter articles and images for veterinary practices to use on their social media channels and will include information on the cost of dairy cow lameness and tips to manage lameness.
Rose Jackson BVSc DBR CertVBM MRCVS is the farm clinical director at Scarsdale Vets which has already trialled the new materials. She said: “The ‘Wave Goodbye to Pain’ social media content has ensured that we are able to post eye-catching and thought-provoking content to continue to engage with our clients and raise awareness of the ‘triple works’ approach to lameness in cows, which includes using a NSAID such as Ketofen, alongside a trim and block for a more complete recovery from lameness than trimming alone.”
The ‘Wave Goodbye to Pain’ campaign was launched following a study by Nottingham University which revealed that NSAIDs have a synergistic effect when given alongside effective hoof trimming and blocking to treat lameness1.
The study looked at claw horn disease of the hind foot and found that trimming alone resulted in a 69% rate of return to mobility without lameness in 35 days. Adding a block into an effective trimming protocol raised the success rate to 72%; trimming and administering a NSAID raised it to 76%. Interestingly, using all three techniques together - trimming, applying a block and administering an NSAID - resulted in 85% of cases being successfully resolved (Mobility score or 0 or 1).
Gemma Robinson BVM BVS MRCVS, ruminant veterinary adviser at Ceva Animal Health, said: “The study highlights that effective and prompt pain relief with NSAIDs can quickly help restore animals back to full productivity. Attitudes on the use of pain relief have changed significantly over the last 10 years and dairy farmers can have a positive influence by ensuring they recognise the value of NSAIDs and prioritise their use on-farm. It is important that vets discuss NSAIDs with their clients, both to manage illness and for routine procedures, and our ‘Wave Goodbye to Pain’ campaign will help encourage farmers to think about their current pain management plan, take action and seek help from their vet.
“Some concerns have been raised that the issues associated with antimicrobial resistance and antibiotic administration are causing farmers to avoid the use of all injectable treatments. We need to be clear that NSAIDs are anti-inflammatories, not antibiotics, and it is important they are used for pain management, fever and the clinical signs associated with many common conditions. With zero milk-withhold NSAIDs available - there really is no reason to hesitate when it comes to administering pain relief in otherwise healthy cattle.”
For more information on the ‘Wave Goodbye to Pain’ campaign visit the website designed for farmers (www.wavegoodbyetopain.co.uk), contact your local Ceva territory manager or call 01494 781510.
To request a copy of the ‘Wave Goodbye to Pain’ social media pack (including pre-developed posts and images which you can send out to your own clients), speak to your Ceva territory manager or email: cevauk@ceva.com with your name, practice name and address details.
Andrea Tarr BPharm MSC MRPharmS, the founder and director of Veterinary Prescriber said: "Prescribing is a neglected aspect of veterinary practice. When it comes to making treatment decisions, vets are very poorly supported by their professional organisations, the pharmaceutical industry has a hugely distorting influence and there's a lack of access to really helpful information.
"We're determined to use the expertise in Veterinary Prescriber to change this, and support vets in their use of medicines in the best interests of animals, their owners and the environment.
"With this in mind, we start the year with a learning module of good veterinary dispensing practice."
The module explains what constitutes a well-run dispensary, including how to organise, handle and store medicines correctly. It reviews the legal classifications of medicines, including controlled drugs and the cascade. It also considers why dispensing errors occur and what to do when they happen.
Veterinary Prescriber says its modules are evidence-based, peer-reviewed and independent of the pharmaceutical industry.
Subscription costs £9.95 per month, which you can cancel any time. To subscribe, visit: www.veterinaryprescriber.org
Part of the Pets at Home Vet Group, the new centre was originally set for a Spring/Summer 2020 opening, but the COVID-19 pandemic and subsequent lockdown set launch plans back to later in the year.
The 24/7 referral centre, which is led by Dr Sam Woods and Professor Dick White as co-Clinical Directors, takes referrals in orthopaedics, internal medicine, neurology, soft tissue surgery, diagnostic imaging and anaesthesia.
Sam said: "We are thrilled to finally be able to officially open our centre this week and to start welcoming patients from the surrounding area and throughout Scotland.
"This has been a strange and difficult year for us all, and as a profession we have faced some hard months. We hope our new referral hospital will be a great asset to the local first opinion professionals, as an extra support with any specialist referral cases, and we are really looking forward to building relationships with them.
"We are lucky to have a great team of veterinary Specialists, nurses and support colleagues at VSS, who are all dedicated to offering the best service and care possible. We are all excited to see what the next few months will bring.
The centre, based at Deer Park in Livingston, will also provide a CPD programme and internship and residency opportunities to those in the profession.
Professor Dick White said: “Since its original inception, our vision for VSS has always been to create a world-class facility, with state-of-the-art technology and outstanding levels of care, and it feels great that we have finally been able to open the doors, welcome patients in and start on our journey.
"We hope the referral centre not only supports local vets and pets, but also fosters new talent and helps develop the next generation of veterinary professionals through our CPD and Internship offering. We are looking forward to what the future will hold."
The platform, which is available to Premier Pet Care Plan and Animal Healthcare clinics, is designed to help practices increase the number of sign-ups to health care plans.
Romain Regnier (pictured right), PVA’s Business Analyst Manager said: "The current situation has accelerated the need for a digital transformation.
"To help vet practices reach this goal, we have created a highly customisable digital sign-up solution, which mirrors the practice’s branding and can be used in communications to the customer, giving you more possibilities to promote your plans."
With a digital platform, practices can now encourage owners to sign up whilst waiting - socially distanced - outside, or from home.
Debbie Saunders, PVA’s Customer Experience Manager said: "It’s a two-pronged solution; reducing the impact that limited interactions with clients is having on health care plan signs ups and allowing practices to advertise their plans more efficiently.
We are encouraging practices to post about their new digital sign-up links on social media, so pet owners complete their forms anywhere. It will make a big difference to veterinary staff, reducing the amount of administrative pressure from plans but also allowing a direct call to action from advertising."
Each practice will be given unique urls, tiny urls and QR codes which link to the platform, alongside additional marketing materials. The marketing packs contain some customisable content, including social media assets, website banners and printable posters, all free to use to promote the new sign-up platform.
The digital sign-up platforms come with personalisation options, allowing practices to customise their webpage with their own logos, text, and branding, with the help of their PVA trainer.
If you are a Premier Pet Care Plan or Animal Healthcare clinic and are interested in integrating a digital sign-up form into your practice, contact your PVA trainer or call 0117 370 0300 .
Kruuse UK has expanded the well-known Buster range of “elizabethan” collars with the introduction of a Buster Comfort Collar. This new design is softer and more flexible and features a soft rubber outer edge for better comfort for the animal and is kinder to its surroundings.
Kruuse says prolonged use can make the edges of strong, rigid plastic collars brittle and ragged, especially with active animals, which is why the Comfort Collar was developed to alleviate this problem in such situations. Manufactured out of environmentally-friendly 100 per cent polypropylene, these collars still feature the quick-fastening system found on the Buster Clic Collar and are fully transparent to allow the animal all-round vision. The Buster Comfort Collars are available in seven sizes ranging from 7.5 to 30cm. For further information, please contact: Andrew Groom, Country Manager, Kruuse UK Ltd. Telephone: +44 (0) 1977 681523. E-mail: andrew.groom@kruuse.com.
In a European first, Pfizer Animal Health is conducting a major study in over 2000 dogs with Trocoxil, its new NSAID which delivers continuous analgesia for a month.
According to the company, Trocoxil has already been granted a licence by the EMEA and pre-authorization studies have already shown once-monthly Trocoxil to be at least as safe and effective as daily carprofen. However, the monthly dosing regimen represents such a big step from the currently used approach of daily NSAID dosing, that Pfizer has decided to initiate the study before launching the product in order to closely monitor and manage the introduction of Trocoxil to the veterinary market.
Jolian Howell, Associate Director Companion Animal Marketing for Pfizer said: "A drug with such a unique dosing regimen should be introduced in a controlled and managed way, and this study is part of that commitment by Pfizer Animal Health."
This large post-approval study, conducted under veterinary control as a User Experience Study, will enable a similar comparison with carprofen to be made in a much larger patient population. In fact it will be sufficiently large to provide product-specific safety information, such as any differences in the incidence of side-effects.
The randomised, parallel group study is being conducted in more than 100 veterinary clinics throughout France, Germany and the UK. Each dog will receive up to 6 months of treatment during which time it will be assessed every month by the veterinary surgeon.
Trocoxil, a preferential COX-2 inhibitor, has a unique pharmacological profile which means that a single oral dose provides continuous pain relief for a whole month.
Jolian added: "This study will provide veterinary surgeons with an opportunity to experience the benefits of using Trocoxil to treat OA continuously over a period of months. It will also give them the opportunity to assess the benefits this offers the owner."
Additional credit is given if the display includes a den, and the top ten displays win a luxury chocolate hamper.
Ceva says the aim of the exercise is to highlight preventative steps pet owners can take to manage their pets' firework fears and the benefits of building a den to help calm and reassure dogs during the firework festivities,
Claire Russell, pheromone product manager at Ceva Animal Health, said: "Our display competition is one of the highlights of the veterinary practice year with veterinary professionals creating innovative displays that capture the imagination of their clients and help educate them on the preventative measures that they can adopt at home to help manage their pet’s firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your local Ceva territory manager.